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Abstract
We have reported a correlation between hypothalamic expression of Creb-binding protein
(Cbp) and lifespan, and that inhibition of Cbp prevents protective effects of dietary restriction
during aging, suggesting that hypothalamic Cbp plays a role in responses to nutritional status
and energy balance. Recent GWAS and network analyses have also implicated Cbp as the
most connected gene in protein-protein interactions in human Type 2 diabetes. The present
studies address mechanisms mediating the role of Cbp in diabetes by inhibiting hypothalamic
Cbp using a Cre-lox strategy. Inhibition of hypothalamic Cbp results in profound obesity and
impaired glucose homeostasis, increased food intake, and decreased body temperature. In
addition, these changes are accompanied by molecular evidence in the hypothalamus for
impaired leptin and insulin signaling, a shift from glucose to lipid metabolism, and decreased
Pomc mRNA, with no effect on locomotion. Further assessment of the significance of the met-
abolic switch demonstrated that enhanced expression of hypothalamic Cpt1a, which promotes
lipid metabolism, similarly resulted in increased body weight and reduced Pomc mRNA.
Introduction
The growing prevalence of type 2 diabetes associated with obesity constitutes one of the great-
est threats to world health in the 21st century [1], but mechanisms contributing to these syn-
dromes remain to be elucidated. Nutrient-sensing hypothalamic neurons constitute a key
locus for sensing and regulating energy balance and glucose metabolism, so mechanisms
mediating these hypothalamic functions are of general concern. While hypothalamic sensing
of leptin and insulin mediate aspects of energy and glucose homeostasis [2], specialized hypo-
thalamic neurons also sense glucose by mechanisms similar to those of pancreatic beta cells
[3], and these neurons can regulate blood glucose [4]. Hypothalamic glucose sensing neurons
have long been hypothesized to play a role in regulating energy balance [5], but the role of
these neurons in regulating energy balance remains to be determined. Nevertheless recent
studies have suggested that a metabolic shift away from hypothalamic glucose metabolism and
toward hypothalamic lipid metabolism promotes obese phenotypes [6,7].
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We previously reported that hypothalamic expression of Creb-binding protein (Cbp) posi-
tively correlates with lifespan across 5 mouse strains [8]. More recently we have observed that
dietary restriction induces hypothalamic Cbp in mice, associated with protective effects against
proteotoxicity [9]. Similarly, dietary restriction in Caenorhabditis elegans induces Cbp, and
blocking this induction prevents protective effects of dietary restriction during aging [8]. In
addition, recent GWAS and network analyses have implicated Cbp as the most connected gene
in protein-protein interactions in Type 2 diabetes [10]. These reports suggest a function for
Cbp in nutrient sensing and energy balance.
The present studies examined the role of hypothalamic Cbp in energy balance and glucose
homeostasis. These studies demonstrate that inhibition of hypothalamic Cbp produces robust
obese phenotypes entailing both increased food intake and reduced body temperature, associ-
ated with impaired glucose homeostasis. These changes are associated with a hypothalamic
molecular profile that indicates a shift away from glucose metabolism and toward lipid metab-
olism, even in pair-fed and weight-matched controls, supporting that this molecular profile
causes, rather than is a result of, the obese phenotypes. Further supporting a causal role, we
demonstrate that enhanced hypothalamic expression of carnitine palmitoyltransferase 1A
(Cpt1a), a key enzyme promoting lipid metabolism, produces similar obese phenotypes, asso-
ciated with reduced hypothalamic of hypothalamic Pro-opiomelanocorticotropin (Pomc).
These studies demonstrate that reduced hypothalamic Cbp promotes obese phenotypes, plausi-
bly in part by enhancing hypothalamic lipid metabolism and reducing hypothalamic glucose
metabolism, associated with reduced hypothalamic Pomc.
Materials and Methods
Animals
Cbp(flox/flox) breeding pairs were received from the Jan van Deursen laboratory (Mayo Clinic,
Rochester, MN); these were produced as described [11]. All mouse studies were specifically
approved with permission and in accordance with the Institutional Animal Care and Use
Committee (IACUC protocols 12–0044 and 12–0169) from the Icahn School of Medicine at
Mount Sinai. Mice were kept under a 12-hour light: 12-hour dark cycles.
Surgical procedures and viral delivery
Cbp inhibition by Cre recombinase viral delivery was carried out as described[12]. Surgeries
were carried out in 8–10 week old mice. Animals were anesthetized using isoflurane and
infused with adeno-associated virus expressing Cre-recombinase (AAV2/8.CMV.HI.
eGFP-Cre.WPRE.SV40), or control (AAV2/8.CMV.PI.eGFP.WPRE.bGH). Viral serotypes
AAV2/8 (Cre-recombinase or control) were purchased from Penn Vector Core at the Univer-
sity of Pennsylvania. AAV2/9.CPT1A and control (AAV2/9.mCherry) driven by the cytomeg-
alovirus promoter were packaged by Virovek and Neurologix Inc., respectively. Two different
serotypes of AAV were used due to availability of the respective vectors from their respective
sources. An infusion cannula was introduced at 3mm/10s to target the mediobasal hypothala-
mus using coordinates: AP—1.5mm; ML ± .35mm; DV 6mm from bregma. One μl per hemi-
sphere was infused (1μl/min), cannula was left to rest for 7 minutes and removed 1mm/min
(first 2mm) and then 1mm/15s. After surgery animals were individually caged, where they
were monitored and allowed to recover in warmed cages for up to 2 hours in order to prevent
hypothermia. Animals were monitored daily and evaluated for any wound complications or
infections for the duration of the experiments; any animals that lost more than 20% in body
weights was sacrificed. Virus expression was corroborated by immunohistochemistry or
RT-PCR where applicable.
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Immunohistochemistry
Animals were perfused using cold 4% paraformaldehyde in PBS as described[13]. Brain was
extracted and placed in 4% paraformaldehyde at 4˚C overnight. Free-floating sections were
prepared by slicing at a 75μm thickness using a vibratome and collected in PBS. Brain slices
were washed and blocked for 1.5 hours in 5% normal goat serum and 0.3% Triton X. Slices
were incubated with Anti-CBP (SC-1211; 1:100) (Santa Cruz Biotechnology, Dallas, TX) O/N
at 4˚C. After incubation sections were stained with Alexa Fluor 658 Anti-rabbit IgG (A-11011;
1:400) and Hoescht (H1399; 2μg/ml) (Life Technologies). Sections were then mounted on
slides using Fluoromount G (Beckman Coulter, Fullerton, CA). All images were acquired with
a Zeiss LSM 780 confocal microscope using an 10x Neofluar objective. 1024x1024 12 bit
images were captured using ZEN 2012 version 8.1, and processed in Fiji. CBP immunopositive
cells from a single slide (75μm thickness) per animal that included the infusion site in the med-
iobasal hypothalamus using an ROI mask (S1 Fig) of the same area were counted and evalu-
ated using a blinded design and the Analyze Particle feature in Fiji.
Blood glucose and insulin measurements
Tail blood was collected and blood glucose was measured using a Bayer Contour glucose
meter (Bayer, Mountain View, CA). Glucose tolerance tests were carried out after a 4-hour fast
followed by an intraperitoneal (i.p) injection of 20% glucose in saline adapted to body weight
(10μl/g). Blood insulin was obtained using ultra-sensitive mouse insulin ELISA kit (Crystal
Chem, Downers Grove, IL).
Food administration and animal records
All animals were individually caged after virus injections. Food intake was measured 2 weeks
after viral delivery. Any spilled food was collected and subtracted from food intake measure-
ments. Two control groups injected with either AAV-Cre or AAV-GFP were allowed free
access to chow diet. Another two experimental groups were set up using the following protocol
to match body weights from the time of surgery. The latter were weighed every day and given
appropriate grams of food to maintain original body weight. To study energy expenditure
starting one week after surgery, AAV-Cre or AAV-GFP infused groups were pair-fed by pro-
viding food pellets 1h before lights out. Animals received the NIH-31 chow formula (Harlan
Teklad Laboratories, Madison, WI), or high fat diet 20% protein, 35% carbohydrate, 45% fat).
Core body temperature was recorded after decapitation via rectal probe using IT-1E thermo-
couple microprobe and a Bat-12 thermometer (Physitemp, Clifton, NJ).
Quantification of mRNA
Animals were sacrificed by decapitation after a brief exposure to carbon dioxide. Brain tissue
and dissections were performed in an ice-cold brain block as previously described[7]. Hypo-
thalamic dissections included the area represented in pictures and diagram on Fig 1A. Tissue
was frozen in dry ice and stored at -80˚C. RNA was extracted using Qiazol reagent and miR-
NAeasy kit (Qiagen, Redwood City, CA). RNA was measured using a nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). cDNA was made using
500ng of RNA using RT2 First Strand Kit (SABiosciences, Frederick, MD). Data were gathered
as Ct (threshold cycle) values obtained from ABI SDS software. Relative mRNA levels were
determined by standard ΔΔCt methods and were expressed in fold change based on control
AAV-GFP or AAV-mCherry animals when appropriate. 200ng of RNA were used in a custom-
made nCounter Codeset (Nanostring Technologies, Seattle, WA) and were carried out in our
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facilities according to manufacturer protocols. Data was extracted using nSolver Analysis Soft-
ware 1.1 (Nanostring Technologies, Seattle, WA) and values were normalized to positive controls
and stable housekeeping transcripts (Hprt, Hsp90ab1, Ppia, Rn18s), which were not influenced
by experimental conditions. Probes and RT-PCR primers utilized are listed in the S1 Table.
Statistical analysis
All animal physiological records were analyzed using PRISM 5 Software using 2-way ANOVA
followed by Bonferroni, or Student’s t-test where appropriate.
Results
Inhibition of hypothalamic Cbp in Cbpflox/flox mice by AAV-Cre
To study the role of hypothalamic Cbp on energy balance, AAV-Cre-recombinase or control
AAV-GFP was infused directed towards the ventromedial hypothalamus (as described [14])
(1μl per side) of Cbpflox/flox mice (loxp flanking sites in exon 9 of the Cbp gene[11]). The
AAV2/8 serotype was chosen based on publications assessing efficacy and stable expression in
Fig 1. Cbpflox/flox mice infused in the hypothalamus with AAV-Cre show reduced immunoreactivity
and mRNA levels for Cbp. (A) Representative images showing nuclear Hoescht staining (blue),
immunoreactive CBP (red) and colocalization (pink) after 3 weeks hypothalamic infusion of AAV-GFP or
AAV-Cre (B) Number of immunopositive cells ± SEM in the mediobasal hypothalamus (n = 5–6) (C) Murine
hypothalamic Cbp ± SEM quantified by RT-PCR (n = 14–20). (D) Representative images of coronal sections
collected 3 weeks after stereotaxic delivery. Images are ordered from rostral to caudal along with
corresponding Allen Atlas sections for reference [16]. Scale bar = 800 μm.
doi:10.1371/journal.pone.0166381.g001
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other brain areas[15]. Mice were infused and housed singly on a standard chow diet (NIH-31).
Three weeks after infusion, this protocol resulted in a significant reduction of hypothalamic
Cbp mRNA levels (41%) and CBP-immunopositive cells (74%) as indicated by immunohis-
tochemistry using a CBP-specific antibody (Fig 1A–1C). In contrast cell numbers and mor-
phology based on Hoescht staining, total RNA levels, and Sf1 mRNA levels were not affected
by the infusions, demonstrating that inhibition of Cbp did not cause loss of hypothalamic neu-
rons (S2 Fig), consistent with previous studies[12]. Targeting of the virus towards the medio-
basal hypothalamus resulted in robust reduction of Cbp mRNA and immunoreactivity (Fig
1A–1C), but this was also accompanied by noticeable spread of the virus particularly rostrally
and caudally (Fig 1D), including nuclei in anterior sections of the paraventricular and the
medial mammillary nucleus. Additionally, within the same plane of the coronal injections dif-
fused lateral expression in the lateral, tuberal, dorsomedial nuclei was observed.
Inhibition of hypothalamic Cbp increases body weight and food intake and impairs glu-
cose homeostasis. The first week after infusion there were no significant changes in meta-
bolic phenotypes, consistent with the property of AAV to maximally express about 2 weeks
after delivery. Starting at two weeks after infusion, body weights significantly increased in Cre-
Cbp/flox mice vs. GFP-Cbp/flox controls (Fig 2A and 2B), associated with increased food
intake (Fig 2C) and increased adiposity as indicated by increased fat pad weight (Fig 2D).
These robust and early increases in body weight were accompanied by increased baseline
blood glucose, detectable by 2 weeks after infusion (Fig 2E). Similarly, plasma glucose was ele-
vated during glucose tolerance tests in the Cre-Cbp/flox mice 30–120 minutes after a 4-hour
fast followed by a weight-adjusted i.p. injection of glucose (Fig 2F). Strikingly, Cre-Cbp/flox
mice were hyperinsulinemic throughout the glucose tolerance protocol (Fig 2G), reflecting
whole-body insulin resistance as indicated by the computed Matsuda index (Fig 2H) [17].
That insulin levels did not change during the glucose tolerance test may indicate a ceiling
effect, i.e., extreme insulin resistance leads to maximal insulin secretion, which is unresponsive
to further glucose stimulation. Impairments in glucose homeostasis were not due to elevated
corticosterone levels, which were not affected by inhibition of hypothalamic Cbp (Fig 2I),
although the matched body weight group exhibited significantly higher levels of corticosterone
as expected.
Inhibition of hypothalamic Cbp decreases body temperature
Obese phenotypes are associated with decreased core body temperatures, which plausibly indi-
cate a decrease in energy expenditure [18,19]. For example, we have reported that body tem-
perature is reduced in genetically obese ob/ob mice, and this is reversed by transgenic
restoration of central POMC [20]. Inhibition of hypothalamic Cbp significantly reduced body
temperature even in food-restricted animals matched to control for body weight (Fig 3A). To
further assess if Cbp reduction produces obesity through decreased energy expenditure, we
pair-fed Cre-Cbp/flox mice to match control ad lib food intake for 6 weeks. These mice were
monitored daily to ensure that food was completely consumed. After 5 weeks, body weights of
the Cre-Cbp/flox mice were statistically elevated relative to controls (Fig 3B), indicating hypo-
thalamic Cbp may regulate energy balance through both food intake and energy expenditure.
Inhibition of hypothalamic Cbp reduces hypothalamic expression of
Pomc and Bdnf
The hypothalamus is particularly sensitive to metabolic state compared to other brain areas,
and hypothalamic gene expression, particularly hypothalamic Pomc, is especially important in
the regulation of energy balance and glucose homeostasis [7,20]. We therefore characterized
Role of Hypothalamic Creb-Binding Protein in Obesity
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the effect of inhibiting hypothalamic Cbp on hypothalamic gene expression, using a custom-
designed nCounter assay allowing for highly sensitive and reproducible transcript counts with-
out an amplification step [21]. A heat map was generated from this analysis (S3 Fig).
Inhibition of hypothalamic Cbp reduced expression of hypothalamic Pomc (Fig 3C) as well
as Bdnf (Fig 3D) and other gene expression persisted even when body weights were matched
by caloric restriction below pair-fed consumption. Reduced expression of both of these genes
has been demonstrated to cause obesity and impaired glucose homeostasis, and at least par-
tially mediates obese phenotypes in leptin-deficient mice [20,22]. Reduction in hypothalamic
Pomc and Bdnf was consistent with reductions in the expression of leptin receptor (Lepr),
Fig 2. Cbpflox/flox mice infused in the hypothalamus develop an obese phenotype, and associated metabolic
impairments, compared to mice infused with AAV-GFP. (A) Representative physical appearance of control and CBP-
inhibited littermates 5 weeks after infusions. (B) Ad libitum body weight ± SEM on a chow diet (n = 7–8), solid lines = GFP-Cbp/
flox (controls); white bars = Cre-Cbp/flox (experimental). (C) Food intake ± SEM at 2 weeks after virus infusions (n = 7–8). (D)
Visceral fat pad weights ± SEM 5 weeks after virus infusions (n = 8–9). (E) Blood glucose ± SEM at 2 weeks after infusions
(n = 15–16). (F) Blood glucose and (G) insulin ± SEM during glucose tolerance tests at 3 weeks after virus infusions (n = 6).
Solid lines = GFP-Cbp/flox (controls); white bars = Cre-Cbp/flox (experimental). (H) Whole body insulin sensitivity ± SEM as
measured by Matsuda index at 3 weeks after virus injection (n = 6). (I) Corticosterone levels measured 3 weeks after virus
infusions in Ad lib and body weight matched groups (n = 9–7). *, p < .05, **, p < .01. ***, p < .001.
doi:10.1371/journal.pone.0166381.g002
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insulin signaling (Irs4), and glucokinase (Gck) (Fig 3E–3G), all of which mediate hypothalamic
responses to nutritional state [23,24]. Expression of other genes implicated in energy balance,
like Agrp, were not influenced by reducing hypothalamic Cbp, while there was a modest
decrease in Npy (data not shown).
Inhibition of hypothalamic Cbp produces a transcriptional profile
indicating decreased glucose metabolism and increased lipid
metabolism
We have reported that fasting produces a hypothalamic gene expression profile indicating a
shift from glycolysis toward lipid metabolism and alternative pathways for glucose metabolism
[7]. Consistent with the observation that fasting-induced hypothalamic changes would be
expected to produce obese phenotypes in the presence of food, inhibition of hypothalamic Cbp
produced a similar hypothalamic shift away from glycolysis (and toward alternate pathways of
glucose metabolism) and toward increased lipid metabolism (Figs 4 and 5, respectively). As
Fig 3. Inhibition of hypothalamic Cbp reduces body temperature, while impairing neuropeptide signaling. (A) Body temperature ± SEM of control and
knockdown mice fed ad libitum (AL) chow diet or restricted diet to match body weights (Matched BW) (n = 5–10). (B) Body weights ± SEM of control and
knockdown mice fed a fix diet below ad libitum food intake for 6 weeks after virus infusion. Solid lines = GFP-Cbp/flox (controls); white bars = Cre-Cbp/flox
(experimental). Hypothalamic relative transcript abundances ± SEM as measured by nCounter, values are normalized to ad libitum control. White
bars = GFP-Cbp/flox (controls); Solid bars = Cre-Cbp/flox (experimental). Murine genes (C) Pomc, (D) Bdnf, (E) Lepr, (F) Irs4, and (G) Gck (n = 8). *, p < .05.
**, p < .01. ***, p < .001 by 2-Way ANOVA.
doi:10.1371/journal.pone.0166381.g003
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indicated in Fig 4, inhibition of hypothalamic Cbp produces a profile of gene expression
expected to decrease glycolysis. For example, inhibition of Cbp reduces expression of glucoki-
nase, critical for hypothalamic sensitivity to glucose signaling via glycolysis [25]. In addition,
markers for negatively regulated pyruvate dehydrogenase (e.g., increased Pdk4 and decreased
of Pdp1) also suggest reduced glucose utilization from glycolysis [26]. Furthermore increased
expression of G6pdx, and H6pd indicates a shift in glucose metabolism away from glycolysis
towards the pentose pathway [27]. Finally, increased expression of Foxo1, Hif1a, and Txnip,
are all consistent with reduced glycolysis [7].
Inhibition of hypothalamic Cbp increased expression of genes promoting lipid oxidation in
either mitochondria (Cpt1a, Cpt1b, Cpt2; Fig 5A–5C), or peroxisomes (Crot, Acox3; Fig 5D
and 5E). The family of Acyl-Coa thioesterases mediates the oxidation of free fatty acids [28].
Thus, significant increases in Acadl, Acads, and Acadvl support that inhibition of hypothalamic
Cbp increases fatty acid oxidation (Fig 5F–5H). Other genes potentially mediating an increase
Fig 4. Cbp inhibition decreases hypothalamic glycolytic markers. Relative murine transcript abundances ± SEM as measured by nCounter, values are
normalized to ad libitum control. White bars = GFP-Cbp/flox (controls); Solid bars = Cre-Cbp/flox (experimental). Murine genes (A) Pdk4, (B) Pdp1, (C)
G6pdx, (D) H6pd, (E) Foxo1, (F) Hif1a, and (G) Txnip (n = 8). *, p < .05, **, p < .01. by 2-Way ANOVA.
doi:10.1371/journal.pone.0166381.g004
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of free fatty acid metabolism include Apod and Apoe, which facilitate the release of free fatty
acids from triacylglycerides [7,29] (Fig 5I and 5J).
Enhanced expression of hypothalamic Cpt1a increases food intake and
body weight, while reducing Pomc expression
The hypothalamic transcriptional profile observed in Cre-Cbp/flox suggests several mecha-
nisms by which Cbp inhibition could produce obese phenotypes, including through impaired
hormonal (e.g., leptin signaling) or altered nutrient signaling (e.g., switching from glycolysis to
lipid metabolism). Several lines of evidence suggest that inhibiting hypothalamic ß-oxidation
reduces food intake [30–33]. To assess if enhanced hypothalamic ß-oxidation would mimic
effects of inhibition of Cbp, hypothalamic carnitine palmitoyltransferase 1A (Cpt1a), a rate-
limiting for lipid oxidation [34], was infused in an AAV construct targeted to the ventromedial
hypothalamus (VMH). Enhanced expression of Cpt1a (Fig 6A) increased body weight on a
standard chow diet and even more on a high-fat diet (Fig 6B). Obesity was not associated with
hyperphagia on the chow diet, but increased hypothalamic Cpt1a did produce hyperphagia on
the high-fat diet (Fig 6C). Increased hypothalamic Cpt1a also raised baseline blood glucose
before body weight gain (Fig 6D). Finally, the body weight increase after 2 weeks on high fat
Fig 5. Obesity and Cbp knockdown show increased lipid and ketone oxidation markers in the hypothalamus. Relative murine transcript
abundances ± SEM as measured by nCounter, values are normalized to ad libitum control. White bars = GFP-Cbp/flox (controls); Solid bars = Cre-Cbp/flox
(experimental). Murine genes (A) Cpt1a, (B) Cpt1b, (C) Cpt2, (D) Crot, (E) Acox3, (F) Acadl, (G) Acads, (H) Acadvl, (I) Apod, (J) Apoe, (K) Bdh2, and (L) Ucp2
(n = 8). *, p < .05. **, p < .01. ***, p < .001 by 2-Way ANOVA.
doi:10.1371/journal.pone.0166381.g005
Fig 6. Hypothalamic Cpt1a overexpression increases body weight, food intake, blood glucose, insulin, and leptin, while
decreasing Pomc expression. (A) Hypothalamic Cpt1a in control and overexpressing virus (n = 5–7). (B) Ad libitum body weight ± SEM
measured at 4 weeks post-infusions in chow and high fat diet (n = 8–10). (C) Chow and high fat food intake ± SEM measured after
infusions (n = 12–14) (D) Baseline blood glucose ± SEM measured after infusions and on different diets (n = 12–14). (E, F) Insulin and
leptin ± SEM measured under high fat diet (n = 12–14). (G) Hypothalamic Pomc transcripts ± SEM measured by RT-PCR (n = 10–13).
*, p < .05. **, p < .01. ***, p < .001.
doi:10.1371/journal.pone.0166381.g006
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diet was associated with increased baseline insulin, leptin, and decreased hypothalamic Pomc
mRNA (Fig 6E–6G).
Discussion
We have previously reported that expression of hypothalamic Cbp (using the same dissection
as in the present studies) positively correlates with lifespan across 5 mouse strains, and protec-
tive effects of dietary restriction during aging were prevented by inhibition of Cbp [8]. Nutrient
sensing of metabolic status and homeostasis can be largely attributed to hypothalamic
responses, and failure of such mechanisms plausibly promotes obese phenotypes [6]. Whole
body Cbp deletion is embryonic lethal, and while Cbp heterozygous knockout mice are viable,
these animals exhibit developmental complications resulting in distinct phenotypes such as
craniofacial malformations, and decreased body weight [35]. To study the direct role of hypo-
thalamic Cbp without developmental confounds, we inhibited hypothalamic Cbp by infusing
AAV-Cre into adult Cbp-floxed mice, resulting in reduction of immunopositive cells for CBP
by 74% and similar reduction in hypothalamic mRNA. Inhibition of hypothalamic Cbp
resulted in a moderate increase in p300 mRNA (S2 Fig), a homolog of Cbp, suggesting poten-
tial compensatory mechanisms [36]. As previously observed in other studies inhibiting Cbp by
AAV-Cre in the adult brain [12], there was no histological or molecular evidence that this
manipulation produced cytotoxicity. Similarly, inhibition of hypothalamic Cbp did not influ-
ence locomotion (S2 Fig), further supporting that inhibition of Cbp did not produce non-spe-
cific damage (e.g., leptin deficiency and hypothalamic lesions reduce locomotor behavior
[37]).
Inhibition of hypothalamic Cbp in adults resulted in rapid and robust obese phenotypes in
mice on a chow diet, including increased body weight 2 weeks after infusion of AAV-Cre into
Cbp-floxed mice (Fig 2B). Inhibition of hypothalamic Cbp caused robust obese phenotypes
independent of sex, though males were significantly heavier than females (data not shown).
Weight gains were associated with robust elevation of food intake at least 3 weeks after infu-
sion of AAV-Cre and persisted throughout the study (at least 5 weeks post-infusion).
Decreased energy expenditure plausibly also contributed to obesity as indicated by decreased
body temperature, and obesity persisted even when mice were pair-fed to controls (Fig 3B).
Further studies with indirect calorimetry could clarify these mechanisms, although appropriate
normalization remains a major challenge in such studies [38,39].
The obese phenotypes observed after inhibition of hypothalamic Cbp are plausibly medi-
ated in part by reduced hypothalamic expression of Pomc and Bdnf (Fig 3C and 3D). Previous
studies have reported that enhanced hippocampal expression of Cbp increases expression of
Bdnf [40]. Hypothalamic Pomc expression is reduced by fasting and in genetic obesity, and
transgenic enhancement of Pomc in leptin-deficient mice partially reverses obese phenotypes
and completely corrects glucose homeostasis in these mice [41]. Conversely, feeding acutely
activates Pomc neurons, an effect that may be mediated by glucose, leptin and/or insulin [2].
Similarly inhibition of hypothalamic Bdnf produces robust obesity, and Bdnf is stimulated by
glucose and leptin [22]. Remarkably, inhibition of hypothalamic Cbp reduced expression of
genes implicated in all three of the main systems that sense nutritional status (e.g., glucokinase,
the leptin receptor, and insulin receptor substrate). Furthermore inhibition of Cbp appeared to
promote a switch from hypothalamic glucose metabolism toward lipid metabolism, which
could plausibly promote obese phenotypes [6]. These studies test the hypothesis that the obese
and diabetic phenotypes produced by inhibition of Cbp may be mediated in part by induction
of Cpt1a. Inhibition of Cbp induced expression of Cpt1a (and other genes that promote lipid
oxidation), as indicated by qPCR analysis of RNA extracted from our standard ventromedial
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hypothalamus (VMH) dissection. Fasting (which produces pro-obesity phenotypes such as
hyperphagia and reduced metabolic rate) also induces Cpt1a using the same dissection [7].
AAV-mediated enhanced expression of Cpt1a targeted to the same hypothalamic site as
AAV-Cre that inhibited Cbp also produced obese phenotypes. Nevertheless it remains to be
proven that induction of hypothalamic Cpt1a mediates the obese phenotypes produced by
inhibition of hypothalamic Cbp since we did not demonstrate co-localization of the two vec-
tors and they entailed slightly different serotypes (AAV2/8-Cre vs. AAV-2/9-Cpt1a). Neverthe-
less, using a protocol similar to ours, Mera et al., demonstrated that AAV-mediated delivery of
the Cpt1a gene directed to the VMH of rats produced similar obese phenotypes [42], and the
“AAV-infected cells in the hypothalamus were limited mainly to the VMH”. Furthermore, sev-
eral studies appear to produce expression levels comparable to those we demonstrated with the
AAV2/8 serotype [15,43]. In other studies directing similar AAV vectors to the VMN, trans-
fection was also almost entirely confined to the VMN [14], possibly due to relatively imperme-
able interstitial tissue that prevents even small molecules from diffusing out of the VMN [4].
Nevertheless, we cannot be certain that some diffusion or retrograde transport to other areas
of the brain may be responsible for some of the effects of the transfected Cre-recombinase or
Cpt1a. Additionally, although Cbp expression is mostly restricted to neurons (particularly in
the hypothalamus) in the adult murine brain [44], while similarly Cpt1a is found in hypotha-
lamic neurons (although to less extent than the Cpt1c brain isoform) [42,45,46], further studies
targeting glial cells are needed.
In conclusion these studies directly link hypothalamic mechanisms regulating energy bal-
ance and glucose homeostasis to mechanisms mediating effects of dietary restriction, a manip-
ulation that is widely protective against many age-related diseases. Of particular interest,
beyond important canonical mechanisms of energy balance (i.e. leptin, and insulin sensing),
these mechanisms appear to share a key shift away from hypothalamic glucose metabolism
and toward lipid metabolism. Finally, based on the observation that Cbp is a histone acetylase,
we and others have demonstrated that HDAC inhibitors mimic many protective effects of die-
tary restriction, dependent on Cbp [8]. Since the ketone 3-hydroxybutyrate is an HDAC inhib-
itor and is produced by a ketogenic diet, these observations may explain the otherwise
perplexing effects of ketogenic diets to produce weight loss [47,48] and suggests that other
HDAC inhibitors may be useful to treat obesity and diabetes.
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